Halozyme director Connie Matsui to exit board

Published 13/02/2025, 22:50
Halozyme director Connie Matsui to exit board

SAN DIEGO, CA - Halozyme Therapeutics , Inc. (NASDAQ:HALO), a biopharmaceutical company with a market capitalization of $7.4 billion, announced today that board member Connie L. Matsui has decided not to seek reelection at the upcoming 2025 annual meeting of stockholders. Matsui, who has been part of the Halozyme board for nearly 18 years, informed the company of her decision on Monday. The company has demonstrated strong performance, achieving a 68% return over the past year according to InvestingPro data.

The company expressed its gratitude to Matsui for her long service and valuable contributions. Halozyme emphasized that her departure is not due to any disagreements regarding the company's operations, policies, practices, or strategy, nor with the company's management or the Board of Directors.

Halozyme Therapeutics specializes in the development of oncology therapies and is known for its proprietary enzyme technology used in drug delivery. The company's statement clarified that Matsui's decision to leave the board was a personal one and unrelated to any internal disputes or issues with the company's direction.

The news of Matsui's upcoming departure comes as Halozyme continues to navigate the competitive landscape of the biotech industry, focusing on creating innovative treatments for cancer patients.

As Halozyme prepares for its 2025 annual meeting, the process for electing a new director to replace Matsui will commence, with further details to be shared in due course. The company's leadership and the remaining board members will continue to guide Halozyme's strategic decisions and oversee the company's growth.

This announcement is based on a press release statement provided in a recent SEC filing by Halozyme Therapeutics, Inc.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.